B of A Securities Downgrades Vir Biotechnology to Neutral, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Geoff Meacham has downgraded Vir Biotechnology (NASDAQ:VIR) from Buy to Neutral and lowered the price target from $23 to $14.
September 08, 2023 | 11:53 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Vir Biotechnology has been downgraded to Neutral from Buy by B of A Securities, with a lowered price target of $14.
The downgrade from Buy to Neutral by B of A Securities indicates a less optimistic outlook for Vir Biotechnology. The lowered price target from $23 to $14 suggests that the analyst believes the stock is currently overvalued. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100